MedTrace Logo

Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer

NCT01461746 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2017-05-31

No results posted yet for this study

Summary

Previous some studies suggested the addition of chemotherapy to radiation therapy after surgery may have survival benefit in patients with high risk endometrial cancer. In addition, docetaxel plus cisplatin regimen may have similar efficacy with paclitaxel plus carboplatin which is currently used in most cases. However, docetaxel plus cisplatin may cause less toxicity compared to paclitaxel plus carboplatin. Therefore, the investigators aimed to analyze the efficacy of docetaxel plus cisplatin regimen followed by radiation therapy after surgery in patients with high risk endometrial cancer.

Conditions

Interventions

DRUG

Docetaxel

Docetaxel 70mg/m2BSA, q 3 weeks, 3 cycles

DRUG

Cisplatin

Cisplatin 60mg/m2BSA, q 3 weeks, 3 cycles

RADIATION

Radiation therapy

Pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)

Sponsors & Collaborators

  • Boryung Pharmaceutical Co., Ltd

    collaborator INDUSTRY

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Joo-Hyun Nam, M.D., Ph.D. · Asan Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01461746 on ClinicalTrials.gov